16th MEET THE PROFESSOR - DIGITAL EVENT 2020

Advanced International Breast Cancer Course

ASYNC DISTANCE LEARNING
SEPTEMBER 25th, 2020 - SEPTEMBER 24th, 2021

LIVE WEBINAR
OCTOBER 8th (3.50 P.M. - 6.50 P.M.)
OCTOBER 9th (4 P.M. - 6.15 P.M.)
fad.accmed.org
Mortality from breast cancer is declining in most countries thanks to effective screening programs, early diagnosis, molecular characterization of the different subtypes and biology-driven treatments. A multidisciplinary management of breast cancer patients is therefore the key to success and a breast multidisciplinary team should include – besides the “classic” clinical specialties – pathologists, molecular biologists and geneticists. Furthermore, the availability of multiple diagnostic and therapeutic choices, the increasing costs of new technologies and drugs and the issue of sustainability represent a new challenge for socially-responsible clinicians. With this goal in mind, the Programme includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes and issues of sustainability and drug access across countries.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 16th AIBCC will award the 10th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. We also welcome the presentation of posters from participants and the best poster will be awarded during the Award Ceremony.

The Digital Event is addressed to medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists who will have the opportunity to interact with breast cancer leaders and exchange experiences in a friendly atmosphere.
Async Distance Learning
September 25th, 2020 – September 24th, 2021

Programme

Invited lectures will be recorded in advance and launched on the virtual platform on September 25th. All the lectures will take 15’

VIRTUAL SESSION I: EVOLUTION IN CANCER PREVENTION AND DIAGNOSIS

1. Beyond BRCA1/2: Management of women with other predisposition gene mutations - Claudine Isaacs

2. Tumor infiltrating lymphocytes in breast cancer: role in clinical practice - Maria Vittoria Dieci

3. Clinical impact of genomics for HER2+ and TNBC - Aleix Prat

4. New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc) - Giuseppe Viale

VIRTUAL SESSION II: LOCOREGIONAL TREATMENT, LIFE AFTER BC

1. Is it safe to avoid axillary node dissection in SN+ patients? - Elefterios Mamounas

2. PMRT after immediate breast reconstruction: the way forward - Philip Poortmans

3. Hormone replacement therapy after BC treatment - Fedro Peccatori

4. Bone Health - Ingo Diel

5. Follow up: how, who, why - Jacek Jassem
VIRTUAL SESSION III: SYSTEMIC TREATMENT FOR EBC

1. How to identify HR+ who are likely to benefit from adjuvant chemotherapy - Carlo Tondini
2. Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI) - Sibylle Loibl
4. Is immunotherapy ready for prime time for early TNBC? - Hope Rugo
5. Post-Neoadjuvant treatments: achievements and opportunities Pier Franco Conte
6. CDK4/6 inhibitors for early breast cancer - Gabriel N. Hortobagyi

VIRTUAL SESSION IV: ADVANCED BREAST CANCER

1. Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications - Stephen Johnston
2. HER2+ disease: integrating the drug tsunami - Sandra Swain
3. TNBC: challenges and opportunities - Miguel Martin
4. New promising drugs for advanced breast cancer - Giuseppe Curigliano

VIRTUAL SESSION V: AFFORDABILITY OF BREAST CANCER COSTS AND EQUITY IN ACCESS

1. The US system: lights and shadows - Thomas Buchholz
2. Reimbursement process in Italy - Francesco Perrone
3. Real World Evidence in Oncology: Opportunities and Pitfalls - Paolo Bruzzi
4. The wave of biosimilars - Hope Rugo
5. The EBCC 2020 Manifesto: how to translate this to clinical reality Philip Poortmans
Programme
Thursday, October 8th

15.50 Registration of participants

16.00 Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

16.15 Q&A live session on pre-recorded lectures of session I
Evolution in cancer prevention and diagnosis
Chairmen: Pier Franco Conte, Valentina Guarneri
The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- Beyond BRCA1/2: Management of women with other predisposition gene mutations - Claudine Isaacs

- Tumor infiltrating lymphocytes in breast cancer: role in clinical practice - Maria Vittoria Dieci

- Clinical impact of genomics for HER2+ and TNBC - Aleix Prat

- New biomarkers ready for prime time (PDL1, PI3K, BRCA, AR etc) - Giuseppe Viale

16.45 Q&A live session on pre-recorded lectures of session II
Locoregional treatment, life after BC
Chairmen: Pier Franco Conte, Valentina Guarneri
The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- Is it safe to avoid axillary node dissection in SN+ patients? - Elefterios Mamounas

- PMRT after immediate breast reconstruction: the way forward
Philip Poortmans

- Hormone replacement therapy after BC treatment
  Fedro Peccatori

- Bone Health - Ingo Diel

- Follow up: how, who, why - Jacek Jassem

17.15 Clinical Case Discussion

- Clinical case: sentinel node biopsy before/after primary systemic therapy
  Presenter: Tania Saibene
  Discussant: Elefterios Mamounas

- Clinical case: radiation therapy after primary systemic therapy treatment
  Presenter Cristina Falci
  Discussant Philip Poortmans

- Clinical case: pathologic complete response after CT+trastuzumab and pertuzumab?
  Presenter: Federica Miglietta
  Discussant: Sandra Swain

- Clinical case: young patients with TNBC and BRCA+ (discussion on platinum salts, ovarian stimulation for fertility issues, contralateral surgery)
  Presenter: Gaia Griguolo
  Discussant: Hesham Ahmed Gaballah Elghazaly

18.15 Virtual Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2020 and best poster award

18.30 Lecture of the Awardee

18.50 Adjourn
Friday October, 9th

16.00 **Introduction**
Pier Franco Conte, Gabriel N. Hortobagyi, Valentina Guarneri, Philip Poortmans

16.15 **Q&A live session on pre-recorded lectures of session III**
**Systemic treatment for EBC**
Chairmen: Pier Franco Conte, Valentina Guarneri
The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **How to identify HR+ who are likely to benefit from adjuvant chemotherapy** - Carlo Tondini

- **Risk adapted endocrine therapy for HR+ BC (from 5 y tamoxifen to 10 years or more AI)** - Sibylle Loibl

- **Neoadjuvant therapy for HER2+ disease: new data, new standard?** - Valentina Guarneri

- **Is immunotherapy ready for prime time for eTNBC?** - Hope Rugo

- **Post-Neoadjuvant treatments: achievements and opportunities** - Pier Franco Conte

- **CDK4/6 inhibitors for early breast cancer** - Gabriel N. Hortobagyi

16.45 **Q&A live session on pre-recorded lectures of session IV**
**Advanced Breast Cancer**
Chairmen: Pier Franco Conte, Valentina Guarneri
The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **Biomarker driven treatment sequencing for HR+ ABC: attempt to reconcile science and label indications** - Stephen Johnston

- **HER2+ disease: integrating the drug tsunami** - Sandra Swain

- **TNBC: challenges and opportunities** - Miguel Martin

- **New promising drugs for advanced breast cancer** - Giuseppe Curigliano
Q&A live virtual session on pre-recorded lectures of session V
Affordability of Breast Cancer Costs And Equity In Access
Chairmen: Pier Franco Conte, Valentina Guarneri
The authors of the lectures will be connected. Moderators will pose 2-3 questions selected from those arrived in the days before through the virtual platform.

- **The US system: lights and shadows** - Thomas Buchholz
- **Reimbursment process in Italy** - Francesco Perrone
- **Real World Evidence in Oncology: Opportunities and Pitfalls** - Paolo Bruzzi
- **The wave of biosimilars** - Hope Rugo
- **The EBCC 2020 Manifesto: how to translate this to clinical reality** - Philip Poortmans

17.45 **Clinical Case Discussion**

- **Clinical case: molecular tumor board and liquid biopsy**
  Presenter: Giacomo Pelizzari
  Discussant: Hope Rugo

- **Clinical case: oligometastatic disease**
  Presenter: Luisa Carbognin
  Discussant: Gabriel N. Hortobagyi

- **Clinical case: slowly progressive disease**
  Presenter Carlo A. Giorgi
  Discussant P. Franco Conte

18.15 **Conclusions**
Directors

Pier Franco Conte
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Gabriel N. Hortobagyi
Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer Center
Houston (USA)

Philip Poortmans
Past-president of ECCO
Department of radiation oncology
Iridium Kankernetwerk
Wolrijk-Antwerp (B)

Scientific Committee

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Miguel Martin
Medical Oncology Service
Hospital Universitario Gregorio Maraño
Madrid (E)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation
Trust & Institute of Cancer Research
London (UK)

Stefania Migliuolo
Europa Donna Italia
Milan (I)

Sibylle Loibl
German Breast Group
University of Frankfurt (D)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Eleuterios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (F)

Aleix Prat
Medical Oncology Department
Hospital Clinic
Barcellona (E)

Sandra Swain M.
Research Development
Georgetown University Medical Center
Washington (USA)
Speakers

Matti S. Aapro  
Paolo Bruzzi  
Epidemiologist  
Genova (I)

Thomas Buchholz  
Radiation Oncology  
Scripps Memorial Hospital La Jolla  
MD Anderson Cancer Center  
Houston (USA)

Luisa Carbognin  
Division of Gynecologic Oncology, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Roma (I)

Giuseppe Curigliano  
Department of Oncology  
European Institute of Oncology  
University of Milan (I)

Maria Vittoria Dieci  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Ingo Diel  
Gynaecology Unit  
Praxisklinik am Rosengarten  
Mannheim (D)

Cristina Falci  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Carlo Alberto Giorgi  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Gaia Griguolo  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Claudine Isaacs  
Cancer Center  
Georgetown University  
Washington (USA)

Federica Miglietta  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Giacomo Pelizzari  
Medical Oncology  
Oncology Center  
Aviano (I)

Francesco Perrone  
Clinical Trial Unit, National Cancer Institute IRCCS Fondazione Pascale  
Napoli (I)

Hope Rugo  
UCSF Carol Franc Buck Breast Care Center  
Breast Oncology Clinical Trials Program  
San Francisco (USA)

Tania Saibene  
Breast Surgery  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Carlo Tondini  
Division of Oncology  
ASST Papa Giovanni XXIII  
Bergamo (I)

Giuseppe Viale  
Department of Pathology  
European Institute of Oncology  
University of Milano (I)
Award & Poster Session

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2020

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

POSTER SESSION

Participants can send one or more abstracts.

The form (available on website https://meethprofessor.accmed.org) should be filled out by following specific guidelines:
1. Use the capitol letter for the title
2. Indicate each author’s affiliation (that should include institution, department and town)
3. Underline the designated presenting author’s name.
4. Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown in the poster session on the website https://meettheprofessor.accmed.org.

People sending the selected abstracts will have free registration.

Abstracts should be sent within September, 15th. A confirmation will be sent by email within September 20th.
Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME:

**Async Distance Learning**: 9 CME points  
**Live webinar**: 6 CME points

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

The credit certification is subject to:
- Professions/specializations should correspond to those which have been accredited for CME
- attendance at the 100% of the async distance learning and webinar live on the platform fad.accmed.org
- the completion of the Meeting evaluation online form available at the end of the each CME activity
- completion of the final questionnaire (at least 75% of correct answers).

We would like to remind all participants that only 1/3 of CME can come from a sponsorship.

**Official Language**

The official language of the Meeting is English. No simultaneous translation will be provided.
Registration

The registration fee includes async distance learning and webinar of October, 8th and 9th:
€ 180,00
€ 100,00 for graduate students and nurses

To register, please send:
• registration form duly filled out;
• privacy statement and consent to the use of personal data (as in the back of the form);
• payment
to Accademia Nazionale di Medicina - Galleria Ugo Bassi, 2 40121 Bologna (fax 0039 51 0569162 - e.mail: info.bologna@accmed.org, within September 15th, 2020.

Online registration is possible on the website
http://meettheprofessor.accmed.org

By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat. Incomplete registration will NOT be admitted. The registration will be confirmed by e-mail, please put your e-mail address on the registration form.

CANCELLATION
• In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.
With the patronage of

INSTITUTIONS

1222 - 2022
800 ANNI
Università degli Studi di Padova
DiSCOG

Rete Oncologica Veneta

Istituto Oncologico Veneto, I.R.C.C.S.

AZIENDA OSPEDALIERA UNIVERSITARIA

SCIENTIFIC SOCIETIES

Aiom

CIPOMO

Comprehensive Cancer Centre

ESTRO